Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 11,389 shares, a growth of 25.6% from the February 12th total of 9,071 shares. Based on an average daily volume of 20,191 shares, the short-interest ratio is presently 0.6 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 20,191 shares, the short-interest ratio is presently 0.6 days.

Institutional Investors Weigh In On Pharming Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC grew its stake in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the last quarter. Millennium Management LLC acquired a new stake in Pharming Group in the 4th quarter worth approximately $360,000. SmartHarvest Portfolios LLC acquired a new stake in Pharming Group in the 4th quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Pharming Group during the 2nd quarter worth approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Weiss Ratings lowered shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Thursday. Oppenheimer restated an “outperform” rating and set a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research note on Friday. Finally, HC Wainwright set a $37.00 price objective on Pharming Group and gave the company a “buy” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Pharming Group Stock Down 4.2%

NASDAQ:PHAR traded down $0.63 during midday trading on Friday, reaching $14.51. 35,943 shares of the stock traded hands, compared to its average volume of 20,159. The stock has a market capitalization of $1.02 billion, a PE ratio of 1,451.00 and a beta of 0.04. Pharming Group has a 12-month low of $7.50 and a 12-month high of $21.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59. The business has a 50-day moving average of $17.21 and a two-hundred day moving average of $16.09.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.08). The firm had revenue of $106.50 million during the quarter, compared to analysts’ expectations of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. On average, equities analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Key Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.